Vnitr Lek 2020, 66(2):104-110 | DOI: 10.36290/vnl.2020.017

Blood vessel ageing and vascular memory

Jan Václavík
Centrum pro hypertenzi, I. interní klinika - kardiologická, FN a LF UP Olomouc

As blood vessels age, their structure and function gradually change. This process is influenced by diet and the presence of modifiable risk factors. Blood vessel status can be clinically evaluated by measuring arterial stiffness or ankle-brachial index. The patient's vascular age can be calculated using the SCORE project and indicates what age would have a person with the same calculated cardiovascular risk, whose risk factors were all within the normal range. The vascular age can be positively influenced by nonpharmacological measures, hypolipidemic statin therapy and also by hypertension pharmacotherapy, especially renin-angiotensin-aldosterone system inhibitors. Long-term follow-up of patients enrolled in clinical trials with antihypertensive and hypolipidemic agents suggests the existence of so-called vascular memory, since the beneficial effects of these interventions on reduction of cardiovascular morbidity and mortality persist for many years after completion of these studies. Early initiation of preventive measures has a greater effect.

Keywords: vascular aging, vascular age, cardiovascular risk factors, intervention, metabolic memory, vascular memory.

Published: April 2, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Václavík J. Blood vessel ageing and vascular memory. Vnitr Lek. 2020;66(2):104-110. doi: 10.36290/vnl.2020.017.
Download citation

References

  1. Barton M, Husmann M, Meyer MR. Accelerated Vascular Aging as a Paradigm for Hypertensive Vascular Disease: Prevention and Therapy. Can J Cardiol. 2016; 32(5): 680-686.e4. doi:10.1016/j.cjca.2016. 02. 062. Go to original source... Go to PubMed...
  2. Neves MF, Cunha AR, Cunha MR, Gismondi RA, Oigman W. The Role of Renin-Angiotensin-Aldosterone System and Its New Components in Arterial Stiffness and Vascular Aging. High Blood Press Cardiovasc Prev. 2018; 25(2): 137-145. doi: 10.1007/s40292-018-0252-5. Go to original source... Go to PubMed...
  3. Vlachopoulos C, Xaplanteris P, Aboyans V, et al. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation. Atherosclerosis. 2015; 241(2): 507-532. doi:10.1016/j.atherosclerosis.2015. 05. 007. Go to original source... Go to PubMed...
  4. Laurent S, Marais L, Boutouyrie P. The Noninvasive Assessment of Vascular Aging. Can J Cardiol. 2016; 32(5): 669-679. doi: 10.1016/j.cjca.2016. 01. 039. Go to original source... Go to PubMed...
  5. Task A, Members F, Tendera M, et al. ESC GUIDELINES ESC Guidelines on the diagnosis and treatment of peripheral artery diseases. Document covering atherosclerotic disease of extracranial carotid The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Societ. 2011: 2851-2906. doi: 10.1093/eurheartj/ehr211. Go to original source... Go to PubMed...
  6. Cuende JI, Cuende N, Calaveras‑Lagartos J. How to calculate vascular age with the SCORE project scales: A new method of cardiovascular risk evaluation. Eur Heart J. 2010; 31(19): 2351-2358. doi: 10.1093/eurheartj/ehq205. Go to original source... Go to PubMed...
  7. Cuende JI. La edad vascular frente al riesgo cardiovascular: aclarando conceptos. Rev Española Cardiol. 2016; 69(3): 243-246. doi: 10.1016/j.recesp.2015. 10. 022. Go to original source...
  8. Vráblík M, Piťha J, Blaha V, et al. Stanovisko výboru České společnosti pro aterosklerózu k doporučením ESC/EAS pro diagnostiku a léčbu dyslipidemií z roku 2019. Hypertenze a KV prevence 2019; 2: 68-77. Go to original source...
  9. Lopez‑Gonzalez AA, Aguilo A, Frontera M, et al. Effectiveness of the Heart Age tool for improving modifiable cardiovascular risk factors in a Southern European population: A randomized trial. Eur J Prev Cardiol. 2015; 22(3): 389-396. doi:10.1177/2047487313518479. Go to original source... Go to PubMed...
  10. Papakatsika S, Stabouli S, Antza C, Kotsis V. Early Vascular Aging: A New Target for Hypertension Treatment. Curr Pharm Des. 2015; 22(1): 122-126. doi: 10.2174/1381612822666151109112813. Go to original source... Go to PubMed...
  11. Ong KT, Delerme S, Pannier B, et al. Aortic stiffness is reduced beyond blood pressure lowering by short‑term and long‑term antihypertensive treatment: A meta‑analysis of individual data in 294 patients. J Hypertens. 2011; 29(6): 1034-1042. doi: 10.1097/HJH.0b013e328346a583. Go to original source... Go to PubMed...
  12. Tropeano AI, Boutouyrie P, Pannier B, et al. Brachial pressure‑independent reduction in carotid stiffness after long‑term angiotensin‑converting enzyme inhibition in diabetic hypertensives. Hypertension. 2006; 48(1): 80-86. doi: 10.1161/01.HYP.0000224283.76347.8c. Go to original source... Go to PubMed...
  13. Kanaki AI, Sarafidis PA, Georgianos PI, et al. Effects of low‑dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia. Am J Hypertens. 2013; 26(5): 608-616. doi:10.1093/ajh/hps098. Go to original source... Go to PubMed...
  14. Meng X, Qie L, Wang Y, Zhong M, Li L. Assessment of arterial stiffness affected by atorvastatin in coronary artery disease using pulse wave velocity. Clin Investig Med. 2009; 32(6): 238-243. Go to original source... Go to PubMed...
  15. Ballard KD, Taylor BA, Capizzi JA, Grimaldi AS, White CM, Thompson PD. Atorvastatin Treatment Does Not Alter Pulse Wave Velocity in Healthy Adults. Int Sch Res Not. 2014; 2014: 1-5. doi: 10.1155/2014/239575. Go to original source... Go to PubMed...
  16. Komukai K, Kubo T, Kitabata H, et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY‑FIT study. J Am Coll Cardiol. 2014; 64(21): 2207-2217. Go to original source... Go to PubMed...
  17. Nathan DM, Cleary PA, Backlund JYC, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005; 353(25): 2643-2653. doi: 10.1056/NEJMoa052187. Go to original source... Go to PubMed...
  18. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-Year follow‑up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008; 359(15): 1577-1589. doi: 10.1056/NEJMoa0806470. Go to original source... Go to PubMed...
  19. Simes J, Simes RJ, Hunt D, et al. Long‑term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID trial follow‑up. Lancet. 2002; 359(9315): 1379-1387. doi: 10.1016/S0140-6736(02)08351-4. Go to original source... Go to PubMed...
  20. Sever PS, Chang CL, Gupta AK, Whitehouse A, Poulter NR. The Anglo‑Scandinavian Cardiac Outcomes Trial: 11-year mortality follow‑up of the lipid‑lowering arm in the UK. Eur Heart J. 2011; 32(20): 2525-2532. doi: 10.1093/eurheartj/ehr333. Go to original source... Go to PubMed...
  21. Bosch J, Lonn E, Pogue J, Arnold JMO, Dagenais GR, Yusuf S. Long‑term effects of Ramipril on cardiovascular events and on diabetes: Results of the HOPE study extension. Circulation. 2005; 112(9): 1339-1346. doi: 10.1161/CIRCULATIONAHA.105.548461. Go to original source... Go to PubMed...
  22. Gupta A, Mackay J, Whitehouse A, et al. Long‑term mortality after blood pressure‑lowering and lipid‑lowering treatment in patients with hypertension in the Anglo‑Scandinavian Cardiac Outcomes Trial (ASCOT) Legacy study: 16-year follow‑up results of a randomised factorial trial. Lancet. 2018; 392(10153): 1127-1137. doi: 10.1016/S0140-6736(18)31776-8. Go to original source... Go to PubMed...
  23. Olsen MH, Angell SY, Asma S, et al. A call to action and a lifecourse strategy to address the global burden of raised blood pressure on current and future generations: the Lancet Commission on hypertension. Lancet 2016; 388: 2665-2712. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.